Robert A Carr
Overview
Explore the profile of Robert A Carr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alami N, Carter D, Kwatra N, Zhao W, Snodgrass L, Porcalla A, et al.
PLoS Negl Trop Dis
. 2023 Jul;
17(7):e0011392.
PMID: 37428804
Background: The parasitic filariae responsible for onchocerciasis and lymphatic filariasis are host to an endosymbiotic bacterium, Wolbachia, which is essential to the fertility and development of the parasites. We performed...
2.
Rosebraugh M, Voight E, Moussa E, Jameel F, Lou X, Zhang G, et al.
Ann Neurol
. 2021 Mar;
90(1):52-61.
PMID: 33772855
Objective: The aim was to demonstrate that continuous s.c. infusion of a soluble levodopa (LD)/carbidopa (CD) phosphate prodrug combination effectively delivers stable LD exposure via a minimally invasive and convenient...
3.
Randolph J, Li T, Krueger A, Heyman H, Chen H, Bow D, et al.
Bioorg Med Chem Lett
. 2020 Feb;
30(7):126986.
PMID: 32046903
Our HCV research program investigated novel 2'-dihalogenated nucleoside HCV polymerase inhibitors and identified compound 1, a 5'-phosphoramidate prodrug of 2'-deoxy-2'-α-bromo-β-chloro uridine. Although 1 had a favorable in vitro activity profile...
4.
Krueger A, Chen H, Randolph J, Brown B, Halvorsen G, Heyman H, et al.
Bioorg Med Chem
. 2019 Nov;
28(1):115208.
PMID: 31740203
Hepatitis C virus (HCV) nucleoside inhibitors have been a key focus of nearly 2 decades of HCV drug research due to a high barrier to drug resistance and pan-genotypic activity...
5.
von Geldern T, Morton H, Clark R, Brown B, Johnston K, Ford L, et al.
PLoS Negl Trop Dis
. 2019 Mar;
13(2):e0007159.
PMID: 30818326
There is a significant need for improved treatments for onchocerciasis and lymphatic filariasis, diseases caused by filarial worm infection. In particular, an agent able to selectively kill adult worms (macrofilaricide)...
6.
Emami Riedmaier A, Lindley D, Hall J, Castleberry S, Slade R, Stuart P, et al.
J Pharm Sci
. 2017 Oct;
107(1):495-502.
PMID: 28993217
Venetoclax, a selective B-cell lymphoma-2 inhibitor, is a biopharmaceutics classification system class IV compound. The aim of this study was to develop a physiologically based pharmacokinetic (PBPK) model to mechanistically...
7.
Beig A, Miller J, Lindley D, Carr R, Zocharski P, Agbaria R, et al.
J Pharm Sci
. 2015 May;
104(9):2941-7.
PMID: 25989509
The purpose of this study was to conduct a head-to-head comparison of different solubility-enabling formulations, and their consequent solubility-permeability interplay. The low-solubility anticancer drug etoposide was formulated in several strengths...
8.
Kikuchi R, Lao Y, Bow D, Chiou W, Andracki M, Carr R, et al.
J Pharm Sci
. 2013 Oct;
102(12):4426-32.
PMID: 24122511
Veliparib (ABT-888) is largely eliminated as parent drug in human urine (70% of the dose). Renal unbound clearance exceeds glomerular filtration rate, suggesting the involvement of transporter-mediated active secretion. Clinically...
9.
Innocenti F, Ramirez J, Obel J, Xiong J, Mirkov S, Chiu Y, et al.
Pharmacogenet Genomics
. 2013 May;
23(7):374-81.
PMID: 23670235
Objective: ABT-751, a novel orally available antitubulin agent, is mainly eliminated as inactive glucuronide (ABT-751G) and sulfate (ABT-751S) conjugates. We performed a pharmacogenetic investigation of ABT-751 pharmacokinetics using in-vitro data...
10.
Miller J, Beig A, Carr R, Spence J, Dahan A
Mol Pharm
. 2012 May;
9(7):2009-16.
PMID: 22632106
Recently, we have revealed a trade-off between solubility increase and permeability decrease when solubility-enabling oral formulations are employed. We have shown this trade-off phenomenon to be ubiquitous, and to exist...